The data support a model where the consequences of Nrf2 activity are in part dependent on epithelial or mesenchymal state epigenetic contexts, relevant to the potential therapeutic use of Nrf2 inhibitors or activators in cancer treatment or prevention. Here, NFE2L2 is linked to cancer.